Suppression of plasma free fatty acids reduces myocardial lipid content and systolic function in type 2 diabetes

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 26, Issue 5, 2016, Pages 387-392

  Wolf, P ^a   Winhofer, Y ^a   Krssak, M ^a   Smajis, S ^a   Harreiter, J ^a   Kosi Trebotic, L ^a   Furnsinn C ^a   Anderwald, C H ^a,b,c   Baumgartner Parzer, S ^a   Trattnig, S ^a   Luger, A ^a   Krebs, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CNR   (Italy)

^c Specialized Hospital Complex Agathenhof   (Austria)

Author keywords

Cardiac steatosis; Diabetic cardiomyopathy; Ectopic lipids; Metabolic inflexibility

Indexed keywords

ACIPIMOX; DAPAGLIFLOZIN; FATTY ACID; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; METFORMIN; PLACEBO; RECOMBINANT HUMAN INSULIN; VILDAGLIPTIN; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; PYRAZINE DERIVATIVE;

ADIPOSE TISSUE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BEDTIME DOSAGE; BODY MASS; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DIET THERAPY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY ACID BLOOD LEVEL; FEMALE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HUMAN; LIPOLYSIS; MALE; METABOLIC DISORDER; MIDDLE AGED; MYOCARDIAL LIPID CONTENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; AUSTRIA; BLOOD; CARDIAC MUSCLE; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DOWN REGULATION; DRUG EFFECTS; ENERGY METABOLISM; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; RISK FACTOR; SINGLE BLIND PROCEDURE; SYSTOLE; TIME FACTOR; TREATMENT OUTCOME;

ADIPOSE TISSUE; AGED; AUSTRIA; BIOMARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DOWN-REGULATION; ENERGY METABOLISM; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOLYSIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; PROTON MAGNETIC RESONANCE SPECTROSCOPY; PYRAZINES; RISK FACTORS; SINGLE-BLIND METHOD; STROKE VOLUME; SYSTOLE; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84964199632     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2016.03.012     Document Type: Article

References (26)

1. Shehadeh A., Regan T.J. Cardiac consequences of diabetes mellitus. Clin Cardiol 1995, 18:301-305.
2. Guha A., Harmancey R., Taegtmeyer H. Nonischemic heart failure in diabetes mellitus. Curr Opin Cardiol 2008, 23:241-248.
3. Stanley W.C., Lopaschuk G.D., McCormack J.G. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997, 34:25-33.
4. Wende A.R., Abel E.D. Lipotoxicity in the heart. Biochim Biophys Acta 2010, 1801:311-319.
5. Bayeva M., Sawicki K.T., Ardehali H. Taking diabetes to heart-deregulation of myocardial lipid metabolism in diabetic cardiomyopathy. J Am Heart Assoc 2013, 2:e000433.
6. Harmancey R., Taegtmeyer H. The complexity of diabetic cardiomyopathy: lessons from patients and animal models. Curr Diabetes Rep 2008, 8:243-248.
7. McGavock J.M., Lingvay I., Zib I., Tillery T., Salas N., Unger R., et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 2007, 116:1170-1175.
8. Krššák M., Winhofer Y., Göbl C., Bischof M., Reiter G., Kautzky-Willer A., et al. Insulin resistance is not associated with myocardial steatosis in women. Diabetologia 2011, 54:1871-1878.
9. Rijzewijk L.J., van der Meer R.W., Smit J.W., Diamant M., Bax J.J., Hammer S., et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008, 52:1793-1799.
10. Hammer S., van der Meer R.W., Lamb H.J., de Boer H.H., Bax J.J., de Roos A., et al. Short-term flexibility of myocardial triglycerides and diastolic function in patients with type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 2008, 295:E714-E718.
11. Winhofer Y., Krssak M., Jankovic D., Anderwald C.H., Reiter G., Hofer A., et al. Short-term hyperinsulinemia and hyperglycemia increase myocardial lipid content in normal subjects. Diabetes 2012, 61:1210-1216.
12. Winhofer Y., Krssak M., Wolf P., Anderwald C.H., Geroldinger A., Heinze G., et al. Free fatty acid availability is closely related to myocardial lipid storage and cardiac function in hypoglycemia counter-regulation. Am J Physiol Endocrinol Metab 2015 Apr 15, 308(8):E631-E640. 10.1152/ajpendo.00371.2014. Epub 2015 Feb 10.
13. Wolf P., Krššák M., Winhofer Y., Anderwald C., Zwettler E., Kukurová I., et al. Cardiometabolic phenotyping of patients with familial hypocalcuric hypercalcemia. J Clin Endocrinol Metab 2014, 99:E1721-E1726.
14. Winhofer Y., Wolf P., Krššák M., Wolfsberger S., Tura A., Pacini G., et al. No evidence of ectopic lipid accumulation in the pathophysiology of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 2014, 99:4299-4306.
15. Peterson L.R., Herrero P., Schechtman K.B., Racette S.B., Waggoner A.D., Kisrieva-Ware Z., et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004, 109:2191-2196.
16. Rijzewijk L.J., van der Meer R.W., Lamb H.J., de Jong H.W., Lubberink M., Romijn J.A., et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 2009, 54:1524-1532.
17. Wolf P., Winhofer Y., Anderwald C.H., Krssak M., Krebs M. Intracellular lipid accumulation and shift during diabetes progression. Wien Med Wochenschr 2014, 164:320-329.
18. Schilling J.D., Mann D.L. Diabetic cardiomyopathy: bench to bedside. Heart Fail Clin 2012, 8:619-631.
19. Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: part I: general concepts. Circulation 2002, 105:1727-1733.
20. Tuunanen H., Engblom E., Naum A., Någren K., Hesse B., Airaksinen K.E.J., et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 2006, 114:2130-2137.
21. Halbirk M., Norrelund H., Moller N., Schmitz O., Gotzsche L., Nielsen R., et al. Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function. Am J Physiol Heart Circ Physiol 2010, 299:H1220-H1225.
22. Nuutila P., Knuuti M.J., Raitakari M., Ruotsalainen U., Teras M., Voipio-Pulkki L.M., et al. Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans. Am J Physiol Endocrinol Metab 1994, 267:E941-E946.
23. Lehto H.R., Parkka J., Borra R., Tuunanen H., Lepomaki V., Parkkola R., et al. Effects of acute and one-week fatty acid lowering on cardiac function and insulin sensitivity in relation with myocardial and muscle fat and adiponectin levels. J Clin Endocrinol Metab 2012, 97:3277-3284.
24. van der Meer R.W., Rijzewijk L.J., Diamant M., Hammer S., Schar M., Bax J.J., et al. The ageing male heart: myocardial triglyceride content as independent predictor of diastolic function. Eur Heart J 2008, 29:1516-1522.
25. Kankaanpaa M., Lehto H.R., Parkka J.P., Komu M., Viljanen A., Ferrannini E., et al. Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab 2006, 91:4689-4695.
26. Goodpaster B.H., He J., Watkins S., Kelley D.E. Skeletal muscle lipid content and insulin resistance evidence for evidence for a paradox in endurance-trained athletes. J Clin Endocrinol Metab 2001, 86:5755-5761.